|
|
A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Sigle Dose Study of the Safety and Effiacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
| Third-party funded project |
| Project title |
A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Sigle Dose Study of the Safety and Effiacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO) |
| Principal Investigator(s) |
Prünte, Christian
|
| Organisation / Research unit |
Bereich Spezialfächer (Klinik) / Ophthalmologie USB |
| Project start |
01.02.2012 |
| Probable end |
31.03.2012 |
| Status |
Completed |
| Abstract |
Fördergeber: Allergan Limited, England, 1st Floor, Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL, UK
Screening Stop Feb 2012, Close out visit April 2012, Keine Fördergelder von Basel!
A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Sigle Dose Study of the Safety and Effiacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO) |
| Financed by |
Other sources
|
| |
|
|
MCSS v5.8 PRO. 0.547 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
05/05/2024
Research Database / FORSCHUNGSDATENBANK
|
